Pfizer Strategic Investment Holdings LLC 4

Accession 0000078003-19-000027

CIK 0001662774other

Filed

May 13, 8:00 PM ET

Accepted

May 14, 7:34 AM ET

Size

20.5 KB

Accession

0000078003-19-000027

Form 4

Period: 2019-05-13

10% Owner

Transactions

Conversion
Common Stock
2019-05-13+624,205→ 3,199,973 total
Purchase
Common Stock
2019-05-13$17.00/sh+50,000$850,000→ 3,249,973 total
Conversion
Series A Redeemable Convertible Preferred Stock
2019-05-13−2,360,071→ 0 total
→ Common Stock (2,360,071 underlying)
Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−215,697→ 0 total
→ Common Stock (215,697 underlying)
Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−624,205→ 0 total
→ Common Stock (624,205 underlying)
Conversion
Common Stock
2019-05-13+2,360,071→ 2,360,071 total
Conversion
Common Stock
2019-05-13+215,697→ 2,575,768 total

10% Owner

Transactions

Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−215,697→ 0 total
→ Common Stock (215,697 underlying)
Conversion
Common Stock
2019-05-13+2,360,071→ 2,360,071 total
Conversion
Common Stock
2019-05-13+215,697→ 2,575,768 total
Conversion
Common Stock
2019-05-13+624,205→ 3,199,973 total
Purchase
Common Stock
2019-05-13$17.00/sh+50,000$850,000→ 3,249,973 total
Conversion
Series A Redeemable Convertible Preferred Stock
2019-05-13−2,360,071→ 0 total
→ Common Stock (2,360,071 underlying)
Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−624,205→ 0 total
→ Common Stock (624,205 underlying)

10% Owner

Transactions

Conversion
Common Stock
2019-05-13+2,360,071→ 2,360,071 total
Conversion
Common Stock
2019-05-13+215,697→ 2,575,768 total
Conversion
Common Stock
2019-05-13+624,205→ 3,199,973 total
Purchase
Common Stock
2019-05-13$17.00/sh+50,000$850,000→ 3,249,973 total
Conversion
Series A Redeemable Convertible Preferred Stock
2019-05-13−2,360,071→ 0 total
→ Common Stock (2,360,071 underlying)
Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−215,697→ 0 total
→ Common Stock (215,697 underlying)
Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−624,205→ 0 total
→ Common Stock (624,205 underlying)

Footnotes (3)

[F1]Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.
[F2]Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.
[F3]PVUS purchased 50,000 additional shares of common stock in the Issuer's initial public offering for consideration of $17.00 per share.

Documents

1 file

Cortexyme, Inc.

CIK 0001662774

Entity typeother

IncorporatedDE